Lynn M. Schuchter, MD, examines the transformation of adjuvant therapy for Stage III/IV melanoma, with an overview of relevant clinical trials鈥攊ncluding EORTC 18071, EORTC 1325/Keynote-54 and Checkmate-238鈥攁s well as the efficacy and safety of the agents involved in these studies, ipilimumab, nivolumab, pembrolizumab, dabrafenib and trametinib. Chief of the Division of Hematology Oncology,聽Dr. Schuchter also provides an update on current practice and future directions for melanoma care at Penn Medicine.
